Skandinaviska Enskilda Banken AB publ Trims Holdings in United Therapeutics Corporation $UTHR

Skandinaviska Enskilda Banken AB publ lowered its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 78.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,982 shares of the biotechnology company’s stock after selling 70,978 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in United Therapeutics were worth $7,951,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. Denali Advisors LLC boosted its stake in United Therapeutics by 58.6% during the 3rd quarter. Denali Advisors LLC now owns 1,903 shares of the biotechnology company’s stock valued at $798,000 after acquiring an additional 703 shares during the last quarter. Tobam increased its position in shares of United Therapeutics by 183.9% in the 3rd quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock worth $3,205,000 after purchasing an additional 4,953 shares during the last quarter. State of New Jersey Common Pension Fund D raised its stake in shares of United Therapeutics by 8.2% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 15,147 shares of the biotechnology company’s stock valued at $6,350,000 after purchasing an additional 1,150 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of United Therapeutics by 4.0% during the third quarter. PNC Financial Services Group Inc. now owns 3,564 shares of the biotechnology company’s stock worth $1,494,000 after purchasing an additional 137 shares during the last quarter. Finally, HighTower Advisors LLC grew its stake in United Therapeutics by 14.5% in the third quarter. HighTower Advisors LLC now owns 3,824 shares of the biotechnology company’s stock worth $1,603,000 after purchasing an additional 483 shares in the last quarter. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Stock Down 1.3%

UTHR stock opened at $476.05 on Thursday. The stock has a market cap of $20.50 billion, a PE ratio of 18.04, a price-to-earnings-growth ratio of 2.57 and a beta of 0.85. The firm’s 50-day simple moving average is $485.84 and its 200 day simple moving average is $437.55. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $519.99.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Royal Bank Of Canada upped their price objective on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Jefferies Financial Group reissued a “buy” rating and set a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. HC Wainwright lifted their price objective on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Finally, UBS Group restated a “buy” rating on shares of United Therapeutics in a research report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $509.50.

Insider Activity

In related news, Director Christopher Causey sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $510.00, for a total value of $510,000.00. Following the completion of the transaction, the director directly owned 4,190 shares of the company’s stock, valued at $2,136,900. This represents a 19.27% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $483.25, for a total value of $4,010,975.00. Following the sale, the executive vice president directly owned 36,781 shares in the company, valued at $17,774,418.25. The trade was a 18.41% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 450,714 shares of company stock valued at $218,011,238. Insiders own 10.30% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.